Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molnupiravir in non-hospitalized COVID-19
NCT04575597Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2020
- Primary completion
- May 2022
- Modality
- RNA-Targeting Small Molecules, Metabolically Activated Prodrugs
- Countries
- 23
01
Overview
A Phase 3 trial of molnupiravir in coronavirus disease 2019 (COVID-19), sponsored by Merck & Co.. Started Oct 2020; status: completed.
02
Drugs
molnupiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04575597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04575597.